TODAY ON PHARMALIVE.COM PharmaLive (press release) (subscription) With a demonstrated ability to induce significantly greater ADCC activity over rituximab, TG-1101 is uniquely positioned to take advantage of the NK-cell activating properties exhibited by lenalidomide; providing a strong biological rationale for ... |
